Short Interest in Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) Declines By 23.2%

Biodexa Pharmaceuticals Plc (NASDAQ:BDRX) was the recipient of a significant decline in short interest during the month of February. As of February 28th, there was short interest totalling 36,100 shares, a decline of 23.2% from the February 13th total of 47,000 shares. Currently, 0.1% of the company’s stock are short sold. Based on an average daily volume of 830,300 shares, the days-to-cover ratio is presently 0.0 days.

Biodexa Pharmaceuticals Price Performance

Shares of NASDAQ BDRX opened at $1.90 on Monday. Biodexa Pharmaceuticals has a twelve month low of $1.84 and a twelve month high of $74.00. The company has a 50 day moving average price of $3.91.

About Biodexa Pharmaceuticals

Biodexa Pharmaceuticals Plc, a clinical stage biopharmaceutical company, focuses on developing a pipeline of products for the treatment of Type 1 diabetes and rare/orphan cancers of the brain. Its lead product candidate Tolimidone, a selective activator of the lyn kinase enzyme, currently under Phase II studies for the treatment of Type 1 diabetes.